Roche says study of lymphoma drug shows significant benefit

ZURICH (Reuters) - Swiss drugmaker Roche said on Wednesday a late-stage study of its treatment for slow-growing, or indolent, non-Hodgkin's lymphoma showed significant benefit and met its primary endpoint early. The study showed that people lived significantly longer without disease worsening or death when treated with Gazyva - marketed as Gazyvaro in the European Union and Switzerland - plus bendamustine followed by Gazyva alone, the company said in a statement. Data from the study will be submitted for presentation at an upcoming medical meeting and to the U.S. ...

via Health News Headlines - Yahoo News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://ift.tt/1z9drLJ